Literature DB >> 28694935

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Jason Brayer1, Rachid Baz2.   

Abstract

The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.

Entities:  

Keywords:  ixazomib; multiple myeloma; proteasome inhibitor

Year:  2017        PMID： 28694935      PMCID： PMC5495505          DOI： 10.1177/2040620717710171

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  49 in total

Review 1.  The proteasome.

Authors:  William S Dalton
Journal:  Semin Oncol       Date:  2004-12       Impact factor: 4.929

2.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

3.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

4.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Authors:  Paul G Richardson; Rachid Baz; Michael Wang; Andrzej J Jakubowiak; Jacob P Laubach; R Donald Harvey; Moshe Talpaz; Deborah Berg; Guohui Liu; Jiang Yu; Neeraj Gupta; Alessandra Di Bacco; Ai-Min Hui; Sagar Lonial
Journal:  Blood       Date:  2014-06-11       Impact factor: 22.113

5.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

6.  Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Authors:  M A Dimopoulos; C Chen; A Spencer; R Niesvizky; M Attal; E A Stadtmauer; M T Petrucci; Z Yu; M Olesnyckyj; J B Zeldis; R D Knight; D M Weber
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

7.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

8.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

9.  Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

Authors:  Pieter Sonneveld; Hartmut Goldschmidt; Laura Rosiñol; Joan Bladé; Juan José Lahuerta; Michele Cavo; Paola Tacchetti; Elena Zamagni; Michel Attal; Henk M Lokhorst; Avinash Desai; Andrew Cakana; Kevin Liu; Helgi van de Velde; Dixie-Lee Esseltine; Philippe Moreau
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

10.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316
View more
  5 in total

1.  Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.

Authors:  Armin Ghobadi; Michael P Rettig; Matthew S Holt; Julie K Ritchey; Krista Kennerly; Ezhilarasi Chendamarai; Linda Eissenberg; John F DiPersio
Journal:  Blood       Date:  2018-04-25       Impact factor: 22.113

2.  Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.

Authors:  Jianguo Tao; Venkat Srinivasan; Xiangjiao Yi; Yingchun Zhao; Hengwei Zhang; Xi Lin; Xichao Zhou; Brendan F Boyce; Peter W Villalta; Frank H Ebetino; Koc Kan Ho; Robert K Boeckman; Lianping Xing
Journal:  J Bone Miner Res       Date:  2022-01-22       Impact factor: 6.390

3.  Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.

Authors:  Dan Yue; Xun Sun
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

4.  Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles.

Authors:  Fangfang Shi; Miao Li; Jing Wang; Di Wu; Meng Pan; Mei Guo; Jun Dou
Journal:  Stem Cell Res Ther       Date:  2018-05-21       Impact factor: 6.832

5.  Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.

Authors:  Daniel Stubba; Dennis Bensinger; Janika Steinbacher; Lilia Proskurjakov; Álvaro Salcedo Gómez; Uwe Schmidt; Stefan Roth; Katja Schmitz; Boris Schmidt
Journal:  ChemMedChem       Date:  2019-11-12       Impact factor: 3.466
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.